Skip Navigation


JAC Advance Access originally published online on April 16, 2007
Journal of Antimicrobial Chemotherapy 2007 59(5):1039-1040; doi:10.1093/jac/dkm046
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
59/5/1039    most recent
dkm046v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Goldstein, F. W.
Right arrow Articles by Kitzis, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldstein, F. W.
Right arrow Articles by Kitzis, M. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Correspondence

Comparison of Etest with agar dilution for testing the susceptibility of Pseudomonas aeruginosa and other multidrug-resistant bacteria to colistin

F. W. Goldstein*, A. Ly and M. D. Kitzis

Hospital Saint-Joseph, 185 rue Raymond Losserand, 75014 Paris, France

* Corresponding author. Tel: +33-144123650; Fax: +33-144123685; E-mail: fgoldstein@hopital-saint-joseph.org

Keywords: P. aeruginosa , susceptibility testing , resistance

The first 10% of the full text of this article appears below.

Sir,

Colistin, introduced for clinical use > 45 years ago, has not been widely prescribed because of an alleged poor activity and high toxicity.1

The increasing prevalence of multidrug-resistant Gram-negative bacteria has stimulated the potential indication of colistin in life-threatening infections.

In recent studies, colistin has been considered as an effective and less toxic compound than in older studies, under the conditions of modern patient care and drug monitoring.1,2 Colistin is used parenterally as sodium colistin methanesulfonate, . . . [Full Text of this Article]

Transparency declarations


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
D. Landman, C. Georgescu, D. A. Martin, and J. Quale
Polymyxins Revisited
Clin. Microbiol. Rev., July 1, 2008; 21(3): 449 - 465.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. D. Macia, A. Mena, N. Borrell, J. L. Perez, and A. Oliver
Increased Susceptibility to Colistin in Hypermutable Pseudomonas aeruginosa Strains from Chronic Respiratory Infections
Antimicrob. Agents Chemother., December 1, 2007; 51(12): 4531 - 4532.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. R. Lo-Ten-Foe, A. M. G. A. de Smet, B. M. W. Diederen, J. A. J. W. Kluytmans, and P. H. J. van Keulen
Comparative Evaluation of the VITEK 2, Disk Diffusion, Etest, Broth Microdilution, and Agar Dilution Susceptibility Testing Methods for Colistin in Clinical Isolates, Including Heteroresistant Enterobacter cloacae and Acinetobacter baumannii Strains
Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3726 - 3730.
[Abstract] [Full Text] [PDF]